secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2025-11-21T23:59:59+00:00
Accession:  0001764013-25-000153
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant CMO Michael Geffner departs; consulting through April 2026
---------------------------------------------------------------------

- Michael Geffner, M.D., M.B.A., ceased as Chief Medical Officer effective Nov 21, 2025.
- Departure is part of R&D leadership restructuring under CEO Eric Venker.
- Severance per existing employment agreement; consulting services through April 30, 2026.
- Outstanding equity awards continue vesting during consulting period; accelerated vesting on change in control.
- Option exercise period extended to nine months after consulting ends or original expiration, whichever earlier.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401325000153/0001764013-25-000153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401325000153/imvt-20251121.htm
  HTML page:      https://secwatch.observer/filing/0001764013-25-000153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer